Work

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study

Year: 2014

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2014.02.036

Authors: Susana M. Campos, William E. Brady, Katherine M. Moxley, Roisin E. O'Cearbhaill, Paula S. Lee, Paul A. DiSilvestro, Jacob Rotmensch, Peter G. Rose, Premal H. Thaker, David M. O'Malley, Parviz Hanjani, Rosemary E. Zuna, Martee L. Hensley

Institutions: Dana-Farber Cancer Institute, Roswell Park Comprehensive Cancer Center, University of Oklahoma, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Women & Infants Hospital of Rhode Island, Rush University Medical Center, Cleveland Clinic, Washington University in St. Louis, The Ohio State University, Abington Memorial Hospital

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G215985982, G2453551107, NRG Oncology Network Group Operations Center, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G5996839100, G8494369300, Cancer Center Support Grant, Roswell Park Cancer Center Support Grant

OpenAlex ID: W2065127630

FWCI: 4.122

Cites: 45

Cited by: 35

Related to: 10